---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-25-000094"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:57:14.230436+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inhibrx reports Q3 net loss $35.3M; ozekibart meets primary endpoint in chondrosarcoma

## Summary
- Net loss of $35.3M ($2.28 per share) vs $43.9M ($2.84) in Q3 2024; R&D expense down to $28.5M.
- Cash and equivalents $153.1M at Sept 30, 2025, down from $186.6M at June 30, 2025.
- Ozekibart (INBRX-109) met primary endpoint in registrational chondrosarcoma trial, showing statistically significant PFS improvement.
- Plan to submit BLA to FDA in Q2 2026; expansion cohorts in colorectal cancer and Ewing sarcoma show high response rates.
- $100M debt outstanding; interest expense of $3.2M in Q3 2025.

## SEC filing metadata
- accession: 0002007919-25-000094
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000094/0002007919-25-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000094/inhibrx-20251114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-25-000094
- JSON: https://secwatch.observer/filing/0002007919-25-000094.json
- Plain text: https://secwatch.observer/filing/0002007919-25-000094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.